Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | JCR Pharmaceuticals Co., Ltd.: JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology | 576 | Business Wire | -Oral Presentation at ESGCT Highlights Potential of JCR's Proprietary JUST-AAV Platform to Facilitate More Efficient Delivery While Reducing Liver Tropism- JCR Pharmaceuticals Co., Ltd. (TSE... ► Artikel lesen | |
30.09. | JCR Pharmaceuticals Co., Ltd.: JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress | 977 | Business Wire | JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced today that it will present... ► Artikel lesen | |
29.09. | Dividendenbekanntmachungen (29.09.2025) | 16.341 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1777 EUR ACOM CO LTD JP3108600002 10 JPY 0,0572 EUR ADVANTEST CORPORATION JP3122400009 19... ► Artikel lesen | |
JCR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
15.07. | Acumen, JCR Pharma Join To Develop Oligomer-targeted Enhanced Brain Delivery Therapy For Alzheimers | 1 | RTTNews | ||
15.07. | Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery Therapy for Alzheimer's Disease | 312 | GlobeNewswire (Europe) | Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPreclinical... ► Artikel lesen | |
09.07. | JCR Pharma and Alexion partner on JUST-AAV gene therapy platform | 6 | Pharmaceutical Technology | ||
24.06. | JCR Pharmaceuticals Co., Ltd.: Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by European Commission (EC) | 376 | Business Wire | MEDIPAL HOLDINGS CORPORATION(TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd.(TSE 4552, JCR) today announced that the European Commission (EC) has granted orphan drug designation (ODD) to JR-446... ► Artikel lesen | |
28.03. | Dividendenbekanntmachungen (28.03.2025) | 25.563 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABERDEEN GROUP PLC ADR US00108N1000 0,3716 USD 0,3442 EUR ACOM CO LTD JP3108600002 7 JPY 0,0429 EUR ADVANEX INC JP3213400009 20... ► Artikel lesen | |
23.10.24 | JCR Pharmaceuticals Co., Ltd.: JCR Pharmaceuticals Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress | 495 | Business Wire | - Preclinical Data Demonstrate Potential to Deliver an AAV Gene Therapy Using JCR's Proprietary J-Brain Cargo Technology to Treat Central Nervous System Diseases - JCR Pharmaceuticals Co., Ltd.... ► Artikel lesen | |
16.10.24 | JCR Pharmaceuticals Co., Ltd.: JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress | 540 | Business Wire | JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that it will present preclinical data from its proprietary J-Brain Cargo-applied adeno-associated... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VERTEX PHARMACEUTICALS | 353,85 | +0,45 % | What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet? | ||
DERMAPHARM | 33,000 | +0,61 % | Kurs der Dermapharm-Aktie verharrt auf Vortags-Niveau (31,85 €) | Der Kurs der der Dermapharm-Aktie kommt kaum von der Stelle. Der jüngste Kurs betrug 31,85 Euro. Ein geringes Minus von 0,78 Prozent zeigt die Kurstafel für der Anteilsschein von Dermapharm an. Die... ► Artikel lesen | |
INCYTE | 74,40 | -0,59 % | Oppenheimer stuft Incyte-Aktie auf 'Perform' herab | ||
LIGAND PHARMACEUTICALS | 156,00 | -0,64 % | Ligand Pharmaceuticals: Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance | Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million)... ► Artikel lesen | |
ASTELLAS PHARMA | 9,416 | +1,36 % | Dividendenbekanntmachungen (29.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1777 EUR ACOM CO LTD JP3108600002 10 JPY 0,0572 EUR ADVANTEST CORPORATION JP3122400009 19... ► Artikel lesen | |
CHUGAI PHARMACEUTICAL | 40,420 | -0,93 % | NEC Corporation: NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment | - Identified the potential to reduce the time required to research and predict drug combinations by approximately 50% -TOKYO, June 18, 2025 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701), in collaboration... ► Artikel lesen | |
ONO PHARMACEUTICAL | 10,000 | -0,99 % | Ono Pharmaceutical reports FQ1 results | ||
KYOWA KIRIN | 13,200 | -2,22 % | Kura Oncology, Inc.: Kura Oncology And Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition Of Npm1 And Flt3 Mutations In Patients With Newly Diagnosed Acute Myeloid Leukemia (aml) | - Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML - - FLT3 mutations occur in approximately 30%... ► Artikel lesen | |
CAMBREX | - | - | Cambrex erweitert seine Produktionskapazitäten für Peptide in Waltham, Massachusetts | East Rutherford, New Jersey (ots/PRNewswire) - Cambrex, ein weltweit führendes Auftragsentwicklungs- und Fertigungsunternehmen ("Contract Development and Manufacturing Organization", CDMO), gab heute... ► Artikel lesen | |
KOBAYASHI PHARMACEUTICAL | 28,800 | -1,37 % | Dividendenbekanntmachungen (27.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGC INC JP3112000009 105 JPY 0,6216 EUR ALERUS FINANCIAL CORPORATION US01446U1034 0,21 USD 0,1795 EUR ALICO INC US0162301040 0... ► Artikel lesen | |
BAYER | 27,610 | -0,61 % | AKTIEN IM FOKUS: Pharmawerte proftieren von US-Deal mit Pfizer | FRANKFURT/ZÜRICH (dpa-AFX) - Europas Pharmawerte haben am Mittwoch stark von einem Deal zwischen der US-Regierung und Pfizer profitiert. Der Branchenindex Stoxx Europe 600 Health Care holte fast seine... ► Artikel lesen | |
NOVO NORDISK | 51,39 | +1,62 % | Novo Nordisk Aktie: Wie groß sind die Turnaround-Chancen wirklich? | Bei der Novo Nordisk Aktie gehen die Spekulationen um ein mögliches Turnaround-Szenario weiter. Nach dem tiefen Kurssturz der dänischen Pharma-Aktie von 1.033,20 DKK auf 287,60 DKK zeigen sich im Chart... ► Artikel lesen | |
MERCK KGAA | 119,10 | -0,13 % | Merck KGaA - SMA 200 im Fokus | ||
METSERA | 52,90 | 0,00 % | Metsera, Inc.: Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3 | Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and... ► Artikel lesen | |
HARROW | 41,880 | 0,00 % | Harrow, Inc.: ImprimisRx Announces Leadership Changes | Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading... ► Artikel lesen |